Contact us
닫기
Article Search
닫기

Microbiology and Biotechnology Letters

총설(Review)

View PDF

Molecular and Cellular Microbiology / Biomedical Sciences  |  Clinical Microbiology and Biomedical Sciences

Microbiol. Biotechnol. Lett. 2016; 44(4): 420-431

https://doi.org/10.4014/mbl.1608.08009

Received: August 22, 2016; Accepted: November 13, 2016

The Role of Complement in the Immunologic Microenvironment of Tumor Cells: Potential Therapeutic Targets

Kyeong Beom Jo 1* and Alison Snape 1

Department of Bioscience Education, King’s College London, London WC2R 2LS, United Kingdom

Abstract

Go to

The complement system comprises a set of essential molecules that bridge the innate and adaptive immune responses. Research has focused on how the complement system’s destructive mechanism could potentially be harnessed for cancer treatment. However, cancer subverts the complement system to avoid immunosurveillance. In addition, a complement-triggered biological mechanism that contributes to cancer growth has been identified. Thus, drugs should be designed to homeostatically maintain a normal concentration of complement. This review explores three types of complement-related anti-cancer drugs: therapeutic antibodies, complement inhibitory drugs, and anti-complement regulatory drugs.

Keywords: Complement, immune system, tumour cells, immunosurveillance, inflammation, therapeutics

References

Go to
  1. Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. 1989. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. J. Immunology 67: 525-530.
  2. Bu X, Zheng Z, Wang C, Yu Y. 2007. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol. Res. Pract. 203:163-167.
    Pubmed CrossRef
  3. Bureeva S, Andia-Pravdivy J, Kaplun A. 2005. Drug design using the example of the complement system inhibitors' development. Drug Discov. Today 10: 1535-1542.
    CrossRef
  4. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. 1988. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81: 1122-1128.
    Pubmed KoreaMed CrossRef
  5. Cimino-Mathews A, Foote JB, Emens LA. 2015. Immune targeting in breast cancer. Oncology 29: 375-385.
    Pubmed
  6. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD. et al. 2012. Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189: 4674-4683.
    Pubmed KoreaMed CrossRef
  7. Davis AE, Lu F, Mejia P. 2010. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 104: 886-893.
    Pubmed CrossRef
  8. Donin D, Jurianz K, Ziporen L, Schultz S. Kirschfink M, Fishelson Z. 2003. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. ExpImmunol. 131: 254-263.
    Pubmed KoreaMed CrossRef
  9. Dougan M, Dranoff G. 2009. Immune therapy for cancer. Annual Rev. Immunol. 27: 83-117.
    Pubmed CrossRef
  10. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. 2003. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer. Immunol. Immunother. 52: 638-642.
    Pubmed CrossRef
  11. Ferlay J, SoerjomataramI, Ervik M, Dikshit R, Eser S, Mathers C, et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Available from http://globocan.iarc.fr. Accessed December 2015.
  12. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol.
    CrossRef
  13. Gasque P, Thomas A, Fontaine M, Morgan BP. 1996. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66: 29-40.
    CrossRef
  14. Gmiński J, Mykala-Ciesla J, Machalski M, Drózdz M, Najda J. 1992. Immunoglobulins and complement components levels in patients with lung cancer. Rom. J. Intern. Med. 30: 39-44.
    Pubmed
  15. Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y. et al. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189: 2985-2994.
    Pubmed KoreaMed CrossRef
  16. Guo RF, Ward PA. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
    Pubmed CrossRef
  17. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38:904-910.
    Pubmed CrossRef
  18. Janssen BJ, Halff EF, Lambris JD, Gros P. 2007. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282:29241-29247.
    Pubmed CrossRef
  19. Kempshall E, Thebault S, Morgan BP, Harris CL, Gallimore A. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunol. Cell Biol. 90: 869-871.
    Pubmed CrossRef
  20. Kolev M, Towner L, Donev R. 2011. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz). 59:407-419.
    Pubmed CrossRef
  21. Kraus S, Fishelson Z. 2000. Cell densensitization by sublytic C5Bb-9 complexes and calcium ionophores depends on activatin of protein kinase C. Eur. J. Immunol. 30: 1272-1280.
    CrossRef
  22. Kraus S, Seger R, Fishelson Z. 2001. Involvement of the ERK mitogenactivated protein kinase in cell resistance to complementmediated lysis. Clin. ExpImmunol. 123: 366-374.
    Pubmed KoreaMed CrossRef
  23. Kraut EH, Sagone AL Jr. 1981. Alternative pathway of complement in multiple myeloma. Am. J. Hematol. 11: 335-345.
    Pubmed CrossRef
  24. Kuraya M, Yefenof E, Klein G, Klein E. 1992. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol., 22: 1871-1876.
    Pubmed CrossRef
  25. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J. et al.1996. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum. Pathol. 27: 1329-1335.
    CrossRef
  26. Maness PF, Orengo A. 1977. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34: 87-89.
    Pubmed CrossRef
  27. Markiewski MM, Lambris JD. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727.
    Pubmed KoreaMed CrossRef
  28. Markiewski MM, Lambris JD. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30: 286-292.
    Pubmed KoreaMed CrossRef
  29. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C. et al. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 12251235.
    Pubmed KoreaMed CrossRef
  30. McConnell I, Klein G, Lint TF, Lachmann PJ. 1978. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur. J. Immunol. 8: 453-458.
    Pubmed CrossRef
  31. Morgan BP, Harris CL. 2015. Complement, a target for therapy in inflammatory and degenerative disease. Nat. Rev. Drug Discov. 14: 857-877.
    Pubmed CrossRef
  32. Niculescu F, Badea T, Rus H. 1999. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis. 142: 47-56.
    CrossRef
  33. Niculescu F, Rus H, Van Biesen T, Shin ML. 1997. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158:4405-4412.
    Pubmed
  34. Niculescu F, Rus HG, Retegan M, Vlaicu R. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140: 1039-1043.
    Pubmed KoreaMed
  35. Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K. 1976. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann. N Y Acad. Sci. 276: 303-315.
    Pubmed CrossRef
  36. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly, DC, Wu Y-Q, DeAngelis RA. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004.
    Pubmed KoreaMed CrossRef
  37. Pio R, Ajona D, Lambris JD. 2013. Complement inhibition: promising concept for cancer treatment. Semin. Immunol. 25: 54-64.
    Pubmed KoreaMed CrossRef
  38. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement:a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
    Pubmed KoreaMed CrossRef
  39. Ricklin D, Lambris JD. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275.
    Pubmed KoreaMed CrossRef
  40. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. 2010. Cancer and the complement cascade. Molecul. Cancer Res. 8:1453-1465.
    Pubmed CrossRef
  41. Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49: 133-148.
    CrossRef
  42. Sahu A, Morikis D, Lambris JD. 2003. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. MolImmunol. 39: 557-566.
    CrossRef
  43. Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG. 2000. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur. J. Immunol. 30: 2944-2953.
    CrossRef
  44. Spiller OB, Criado-Garcia O, Rodriguez De Cordoba S, Morgan BP. 2000. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. ExpImmunol. 121: 234-241.
    Pubmed KoreaMed CrossRef
  45. Swann JB, Smyth MJ. 2007. Immune surveillance of tumour. J. Clin. Invest. 117: 1137-1146.
    Pubmed KoreaMed CrossRef
  46. Szebeni J. 2004. The complement system: Novel Roles in Health and Disease. Boston: Kluwer Academic Publishers. 4: 265-304.
  47. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-377.
    Pubmed CrossRef
  48. Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F. et al. 2011. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 51: 4560.
    Pubmed KoreaMed CrossRef
  49. Vagas-Madrazo E, Lara-Ochoa F, Almagro JC. 1995. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. J. Mol. Biol.254: 497-504.
    CrossRef
  50. Woodruff TM, Nandakumar KS, Tedesco F. 2011. Inhibiting the C5-C5a receptor axis. MolImmunol. 48: 1631-1642.
    Pubmed CrossRef
  51. Ytting H, Jensenius JC, Christensen J, Thiel S, Nielsen HJ. 2004. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J. Gastroenterol. 39: 674-679.
    Pubmed CrossRef
  52. Zipfel PF, Skerka C. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.
    CrossRef

Article Tools

Starts of Metrics

Share this article on :

Related articles in MBL

Most Searched Keywords ?

What is Most Searched Keywords?

  • It is most registrated keyword in articles at this journal during for 2 years.